-
Emergency use authorization makes it easier for doctors to use a drug in a manner not specifically approved by the Food and Drug Administration. The FDA granted these drugs this status in March.
-
A paper suggesting hydroxychloroquine increases the risk of death for patients with COVID-19 has been retracted by three of its authors because they were not able to verify the data used in the study.
-
A study of more than 800 health workers, first responders and others finds that taking hydroxychloroquine to prevent COVID-19 is no better than a placebo in preventing the illness.
-
The move comes after the World Health Organization halted clinical trials of the drug as a treatment, citing a study that found no benefit and a higher mortality rate for hospitalized patients.
-
Some scientists think this drug has promise for COVID-19. But controversy around the drug is complicating the job of scientists who just want to find answers.
-
The agency said Friday that using hydroxychloroquine and a related compound, chloroquine, for COVID-19 may cause life-threatening side effects. That warning contradicts the president's own enthusiasm.
-
After President Trump complained, India reversed its export ban on the anti-malaria drug, which Trump has touted as a coronavirus treatment. There's no clinical evidence it works against COVID-19.